Fundraising FoxIntermediate Capital Group — 2023 Investments
1 investments dated 2023 · listed companies and verified rows first · show all
Amolyt Pharmaamolytpharma.comJan 2023 · $138M
Developing therapeutic peptides targeting rare endocrine diseases (past investment).
Co-investorsAndera PartnersATEM Capital FundCTI Life Sciences Fund L.P.EQT Life SciencesKurma PartnersOctalfa+4 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.